Contact us


Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Lung Cancer

Randomized, Placebo-Controlled, Double-Blind Phase 1B/2 Study of U3-1287 (AMG888) in Combination with Erlotinib in EGFR Treatment Naïve Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Chemotherapy

For more information, please visit

Patient Population Investigational Product(s) Phase Status
Non-Small Cell Lung Cancer U3-1287 (AMG 888) IB/II Closed